Travere Therapeutics Inc (NAS:TVTX)
$ 6.35 -0.21 (-3.2%) Market Cap: 483.42 Mil Enterprise Value: 463.14 Mil PE Ratio: 0 PB Ratio: 6.55 GF Score: 58/100

Travere Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 12, 2023 / 07:15PM GMT
Release Date Price: $20.85 (+1.26%)
Luka Kachukhashvili

Hi, everyone. Welcome. It's great to see everyone in person. This is the fourth day of the JPMorgan Healthcare Conference. My name is Luka Kachukhashvili. I'm an associate here in the Healthcare Investment Banking team.

It's my absolute pleasure to introduce Travere Therapeutics. Joining us today will be Eric Dube, the CEO of Travere. With that, I hand it over to you.

Eric M. Dube
Travere Therapeutics, Inc. - President, CEO & Director

Luka, thank you, and JPMorgan for hosting us. I couldn't be more excited and grateful to be able to share the opportunity to talk about Travere. It is perhaps the most important year for us in our 8-year history, but also for the space within rare kidney disease that really were at the forefront of what I believe is a renaissance in being able to bring hope and new therapies for patients living with rare kidney disease.

In my presentation, I will be sharing some forward-looking statements. So I'd encourage you to go to look at our SEC filings for additional language there. But I want to start

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot